|Brand name(s), other common name(s)||ImbruvicaTM|
|Drug type||BTK inhibitor|
|How the drug is given||By mouth|
Ibrutinib has been FDA-approved to treat patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Ibrutinib has also been FDA-approved for chronic lymphocytic leukemia (CLL) patients who have received at least one previous therapy, and CLL patients who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL.
Side effects needing medical attention:Low blood platelet count; diarrhea; low white blood cell count; low red blood cell count; fatigue; muscle and bone pain; swelling of legs and feet; upper respiratory tract infection; nausea; bruising; shortness of breath; constipation; rash; stomach (abdomen) pain; vomiting; decreased appetite; fever; joint pain; mouth sores; sinus infection; and dizziness.
Serious side effects: Bleeding problems; infections; decrease in blood cell counts; kidney problems; second primary cancers.